Tanvex BioPharma Inc - Asset Resilience Ratio
Tanvex BioPharma Inc (6541) has an Asset Resilience Ratio of 3.85% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Tanvex BioPharma Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2018)
This chart shows how Tanvex BioPharma Inc's Asset Resilience Ratio has changed over time. See 6541 total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Tanvex BioPharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Tanvex BioPharma Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$130.28 Million | 3.85% |
| Total Liquid Assets | NT$130.28 Million | 3.85% |
Asset Resilience Insights
- Limited Liquidity: Tanvex BioPharma Inc maintains only 3.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tanvex BioPharma Inc Industry Peers by Asset Resilience Ratio
Compare Tanvex BioPharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Tanvex BioPharma Inc (2016–2018)
The table below shows the annual Asset Resilience Ratio data for Tanvex BioPharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 42.35% | NT$1.90 Billion ≈ $59.75 Million |
NT$4.48 Billion ≈ $141.11 Million |
+15.84pp |
| 2017-12-31 | 26.50% | NT$1.05 Billion ≈ $33.18 Million |
NT$3.97 Billion ≈ $125.17 Million |
-15.17pp |
| 2016-12-31 | 41.67% | NT$1.61 Billion ≈ $50.84 Million |
NT$3.87 Billion ≈ $122.00 Million |
-- |
About Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a biopharmaceutical company, researches, develops, manufactures, and sells biosimilar products in Taiwan and the United States. It focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that… Read more